09:08 AM EDT, 09/06/2024 (MT Newswires) -- Milestone Pharmaceuticals ( MIST ) said Friday that its licensing partner Ji Xing Pharmaceuticals reported that a phase 3 trial in China evaluating etripamil nasal spray to treat paroxysmal supraventricular tachycardia met its primary endpoint.

Ji Xing said the results show a statistically significant greater proportion of patients who took etripamil converted PSVT to normal sinus rhythm compared to placebo. It also said that there were no reported serious adverse effects related to etripamil.

The study, which was conducted by Ji Xing, included 500 patients in more than 40 hospitals in China.

Price: 1.4700, Change: +0.01, Percent Change: +0.68